- Home
- CCSI vs ERAS Comparison
CCSI vs ERAS Comparison
Compare CCSI & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCSI
- ERAS
- Stock Information
- Founded
- CCSI 2021
- ERAS 2018
- Country
- CCSI United States
- ERAS United States
- Employees
- CCSI N/A
- ERAS N/A
- Industry
- CCSI Retail: Computer Software & Peripheral Equipment
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- CCSI Technology
- ERAS Health Care
- Exchange
- CCSI Nasdaq
- ERAS Nasdaq
- Market Cap
- CCSI 475.1M
- ERAS 410.8M
- IPO Year
- CCSI N/A
- ERAS 2021
- Fundamental
- Price
- CCSI $23.20
- ERAS $1.33
- Analyst Decision
- CCSI Hold
- ERAS Strong Buy
- Analyst Count
- CCSI 5
- ERAS 6
- Target Price
- CCSI $27.20
- ERAS $4.83
- AVG Volume (30 Days)
- CCSI 146.8K
- ERAS 1.3M
- Earning Date
- CCSI 05-07-2025
- ERAS 05-20-2025
- Dividend Yield
- CCSI N/A
- ERAS N/A
- EPS Growth
- CCSI N/A
- ERAS N/A
- EPS
- CCSI 4.32
- ERAS N/A
- Revenue
- CCSI $349,374,000.00
- ERAS N/A
- Revenue This Year
- CCSI $1.26
- ERAS N/A
- Revenue Next Year
- CCSI $0.88
- ERAS N/A
- P/E Ratio
- CCSI $5.43
- ERAS N/A
- Revenue Growth
- CCSI N/A
- ERAS N/A
- 52 Week Low
- CCSI $12.67
- ERAS $1.01
- 52 Week High
- CCSI $32.10
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- CCSI 65.46
- ERAS 48.02
- Support Level
- CCSI $19.24
- ERAS $1.37
- Resistance Level
- CCSI $24.03
- ERAS $1.53
- Average True Range (ATR)
- CCSI 0.98
- ERAS 0.13
- MACD
- CCSI 0.55
- ERAS -0.00
- Stochastic Oscillator
- CCSI 83.74
- ERAS 30.86
About CCSI Consensus Cloud Solutions Inc.
Consensus Cloud Solutions Inc is a provider of secure information delivery services with a scalable Software-as-a-Service SaaS platform. It is engaged in fax cloud business. The Company operates in USA, Canada, Ireland, and Other. Geographically, it derives a maximum revenue from the United States. The company's communication and digital signature solutions enable customers to securely and cooperatively access, exchange and use information across organizational, regional, and national boundaries.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.